In-depth, critical analyses of new publications and breaking news concerning antiretroviral drug resistance and HIV clinical care
|
 |
 |
NEW
Antiretroviral Drug Resistance in Non-Subtype B HIV-1
Special guest editor Rami Kantor, M.D., and David Katzenstein, M.D., review the latest data on resistance patterns of non-subtype B viruses from studies around the globe.
|
|
|
NEW
Genotype-Phenotype Discordances
From genotypic mixtures to atypical mutations, Robert W. Shafer, M.D., reviews the six most common causes of discordance between genotypic and phenotypic HIV drug resistance test results.
|
|
|
NEW
Reports from the XI International HIV Drug Resistance Workshop
See From the Podium for conference coverage and meetings reports.
|
|
|
NEW
Does Resistance Testing Effect Better Outcomes? A Review of Published Prospective Trials
Although six prospective studies of HIV drug resistance testing have now been published, their findings are far from harmonious. Hence, the question remains: "What is the clinical value of HIV drug resistance testing?" Michelle Roland, M.D. reviews the literature that keeps us guessing.
|
|
|
NEW
Genotyping: It May No Longer be Just for the Virus
A growing body of evidence suggests that host genotypic factors – not just viral genotypic factors – are responsible for variability in disease progression, response to ARV therapy, and certain drug-mediated toxic and hypersensitivity effects. Robert Shafer, M.D. reports on the influence of host genomic factors on HIV’s natural history and the metabolism of ARV drugs.
|
|
|
Reports from the 9th Conference on Retroviruses and Opportunistic Infections
See From the Podium for conference coverage and meetings reports.
|
|
|
Non-Subtype B Viruses and Drug Resistance
Will lessons with HAART in the U.S. and Europe be applied to the development of strategies for prolonging the efficacy of ARV treatment globally? David Katzenstein, M.D. reviews considerations of drug resistance and drug efficacy in the West vs. similar considerations in resource-poor settings.
|
|
|
Update on FDA Regulation of HIV Drug Resistance Assays
Michelle E. Roland, M.D. returns to the important subject of how HIV drug resistance assays are regulated by the FDA. The current update examines a draft document prepared by FDA to help define regulatory requirements – such as which mutations must be analyzed, and “minimal interpretation algorithm” requirements -- for test manufacturers.
|
|
|
Kaletra: Sorting Fact from Fiction
The durability of antiretroviral activity is dependent on interrelated patient, drug and virus factors. Brian Conway, M.D. reviews the relative contributions of such factors to the promising resistance profile of Kaletra.
|
 |
 |
Highlights From the 3rd European Symposium on the Clinical Implications of HIV Drug Resistance
Mark Wainberg, Ph.D. takes a look at issues of viral fitness, nucleoside-associated mutations, differences among HIV subtypes, and the predictive value of HIV genotyping, as treated of at the 3rd European Symposium on the Clinical Implications of HIV Drug Resistance.
|
|
|
Highlights From the 3rd European Symposium on the Clinical Implications of HIV Drug Resistance
Charles Boucher, M.D., Ph.D. discusses recent data concerning nucleoside-associated mutations and interpretive systems for genotypic HIV drug resistance assays presented at the 3rd European Symposium on the Clinical Implications of HIV Drug Resistance.
|
|
|
Primary HIV Drug Resistance
HIVresistanceWeb’s primary resistance tracker Douglas Mayers, M.D. reviews the latest resistance data from cohorts of adult seroconverters, adult partner pairs and mother and child pairs.
|
|
|
Drug Transporters, Sanctuary Sites and HAART Failure
What is the role of drug transport molecules in the pharmacology of antiretroviral drugs and the development of HIV drug resistance? Douglas Mayers, M.D. reports on the newest data regarding P-glycoprotein and associated genes.
|
|
|
Structured Treatment Interruption: Novel Strategy or Oxymoron?
What do we know about STI in HIV infection? Brian Conway, M.D. and David Katzenstein, M.D. review the latest findings regarding this strategy in acute and chronic infection.
|
|
|
Resistance to Nucleoside Analogs: Update From the 8th CROI
Charles Boucher, M.D., Ph.D. reports on NRTI resistance data presented at the 8th Conference on Retroviruses and Opportunistic Infections (8th CROI).
|
|
|
NNRTI Resistance Update: Using the Old Ones, Looking Toward the New
Brian Conway, M.D. reports from the 8th CROI on new resistance data concerning available and investigational NNRTIs.
|
|
|
New Data on Protease Inhibitor Resistance
Jonathan M. Schapiro, M.D., reports from the 8th CROI on resistance to Kaletra, amprenavir and other PI.
|
|
|
Clinical Information on Resistance Testing: New Clinical Trials and Improvements in Tests and Reports—Part One
Michelle E. Roland, M.D. reports from the 8th CROI on the latest prospective and retrospective data from clinical trials of HIV drug resistance testing in antiretroviral-naive and -experienced patients.
|
|
|
Salvage Therapy: More Data on New Drugs Against Old Targets
Robert Shafer, M.D. reports on salvage strategies from the 8th Conference on Retroviruses and Opportunistic Infections (8th CROI).
|
|
|
New Drugs
Mark A. Wainberg, Ph.D. reports from the 8th CROI on the activity of new PIs, nucleosides, NNRTIs and fusion inhibitors against drug-resistant HIV.
|
|
|
How We Know What We Know About HIV Drug Resistance
Dr. Bob Shafer takes stock of what we currently know about drug resistance, where that knowledge comes from, and where it might lead us. This review focuses on the interpretation of genotypic resistance test results and the four sources of laboratory and clinical data that form the basis of drug resistance knowledge.
|
